Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Accumulated Expenses (2016 - 2026)

Spyre Therapeutics' Accumulated Expenses history spans 11 years, with the latest figure at $26.9 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 2.76% year-over-year to $26.9 million; the TTM value through Dec 2025 reached $26.9 million, down 2.76%, while the annual FY2025 figure was $26.9 million, 2.76% down from the prior year.
  • Accumulated Expenses reached $26.9 million in Q4 2025 per SYRE's latest filing, up from $23.8 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $28.4 million in Q2 2023 to a low of $1.7 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $15.4 million, with a median of $13.3 million recorded in 2021.
  • Peak YoY movement for Accumulated Expenses: tumbled 86.9% in 2021, then surged 522.68% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $14.0 million in 2021, then decreased by 8.5% to $12.8 million in 2022, then rose by 2.11% to $13.1 million in 2023, then skyrocketed by 111.41% to $27.7 million in 2024, then fell by 2.76% to $26.9 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Accumulated Expenses are $26.9 million (Q4 2025), $23.8 million (Q3 2025), and $19.4 million (Q2 2025).